main-img
Back to Home » July 2016 News » Biohaven Reports Dosing of First Subject in Pharmacokinetic and Safety Trial of BHV-4157

Biohaven Reports Dosing of First Subject in Pharmacokinetic and Safety Trial of BHV-4157

July 20, 2016

NEW HAVEN, CT--(Marketwired - July 20, 2016) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") reported today that the Company has begun dosing subjects in its first clinical trial to evaluate the safety and pharmacokinetics of BHV-4157. Biohaven recently received clearance from the FDA on its IND and permission to begin dosing in humans.

Source URL: http://www.marketwired.com/mw/release.do?id=2143791&sourceType=3
Browse News